Glucagon-like Peptide-1 receptor agonists and intracranial aneurysm biology: a testable immunometabolic framework

Unruptured intracranial aneurysms (UIAs) present a preventive-treatment challenge: many lesions are managed with surveillance, and no disease-modifying pharmacotherapy has been established. Retrospective analyses have associated glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure with fewer coded aneurysm rupture-related or nontraumatic subarachnoid hemorrhage events. These studies may include overlapping populations and cannot establish causality or direct effects on the native aneurysm wall. This Perspective examines how systemic metabolic and hemodynamic changes might intersect with endothelial dysfunction, immune activation, proteolysis, and extracellular-matrix remodeling in intracranial aneurysms. Randomized evidence for blood-pressure and inflammatory-marker reductions supports plausible indirect pathways, but their contribution to aneurysm outcomes remains untested. Vascular receptor-localization and deletion studies provide context-dependent mechanistic evidence from other vascular beds; functional GLP-1 receptor engagement in native human aneurysm tissue has not been demonstrated in the evidence reviewed here. A direct-wall hypothesis therefore requires validated receptor localization, pharmacologic accessibility, receptor-dependent signaling, and preservation of wall structure at clinically relevant exposure. Independent observational replication and prospective imaging-biomarker studies should assess systemic mediation alongside local mechanisms. Limited tissue access, uncertain surrogate endpoints, low rupture-event rates, treatment tolerability, and cost constrain translation. The priority is to test these mechanisms and their clinical relevance before considering aneurysm-directed repurposing.